MILAN--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Newron's sarizotan for the treatment of Rett syndrome.